COMMENTARY

What Should We Tell Patients About the Insulin Glargine (Lantus®) Controversy?

Anne L. Peters, MD, CDE, FACP

Disclosures

July 08, 2009

This feature requires the newest version of Flash. You can download it here.


Citations: Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009 Jul 2. [Epub ahead of print].
Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009 Jun 30. [Epub ahead of print].

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....